On March 19, 2024 Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology powered vaccines, reported a Research & Development (R&D) Day focusing on its core AI-Immunology platform (Press release, Evaxion Biotech, MAR 19, 2024, View Source [SID1234641262]). The event will be hosted at our facilities in Hørsholm, Denmark, between 14.00 – 18.00 CET / 9.00 a.m. – 1.00 p.m. EST and can be accessed remotely here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The R&D Day features a series of talks providing in-depth insights into Evaxion’s clinically validated AI-Immunology platform for vaccine target discovery, design and development. AI-Immunology consists of a collection of in-house developed AI building blocks that can be intelligently combined into AI prediction models to address complex healthcare issues related to the immune system. With the AI prediction models, PIONEER, ObsERV, EDEN and RAVEN, we can identify clinically relevant vaccine targets within hours.
Christian Kanstrup, CEO of Evaxion, expresses enthusiasm: "We have been looking forward to this exciting day and welcome everyone interested in learning more about our technology and its potential for saving and improving lives. We believe that we hold a truly differentiated position driven by our validated AI-Immunology platform and the multi-disciplinary capability set we have built around it. The potential of AI-Immunology is evidenced by our strong pipeline of vaccine candidates and existing partnerships."
The presentations during the day will, among other things, cover:
The innovative modular architecture of AI-Immunology, where AI building blocks can be combined into AI prediction models, enhancing scalability
Insights into the novel AI-Immunology building block, EvaxMHC, which is used across the platform, significantly enhancing the predictive capabilities
The clinical validation of the predictive capabilities of the PIONEER model showing a statistically significant improvement in progression-free survival in metastatic melanoma patients
The novel tumor target sources, named Endogenous Retroviruses (ERVs), showing high relevance in low tumor mutation burden cancers, allowing for potentially more effective personal cancer vaccines
The EDEN model outperforms reverse vaccinology finding novel targets in hours instead of years. The EDEN designed EVX-B2 vaccine candidate showing stronger protection than a vaccine candidate developed by GSK’s Gonorrhea
RAVEN introduces novel vaccine concepts to enhance the effectiveness of T-cell-based vaccines
The ObsERV model allows for a novel precision vaccine approach toward addressing cancers which cannot be targeted with standard immunotherapies
Following the R&D Day, a replay of the event presentations will be available on our website.
About AI-Immunology
AI-Immunology is a scalable and adaptable artificial intelligence technology platform at the forefront of vaccine discovery for infectious diseases and cancers. By integrating the collective power of proprietary AI models PIONEER, EDEN, RAVEN, and ObsERV, the platform can model the complexity of the patient’s immune system. AI-Immunology advanced computational modelling swiftly and uniquely identifies, predicts, and designs vaccine candidates, revolutionizing the landscape of immunotherapy by offering a holistic and personalized approach to combat fast-evolving pathogens and malignant cells.